GlassScriptPhysician profile
Colin Leffert
NPI 1881127140
$6,437.50
in general payments reported to CMS, 2019-2025
32 companies · $1,463 in 2025
The $1,463 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $142 · 2021: $821 · 2022: $802 · 2023: $1,121 · 2024: $2,087 · 2025: $1,463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,573 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,573.08 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,949.48 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $717.84 | 2021-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $623.99 | 2020-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $619.27 | 2022-2025 | Tremfya, Stelara, Simponi |
| Regeneron Healthcare Solutions, INC. | $523.81 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $266.82 | 2023-2025 | Omvoh |
| Gilead Sciences, INC. | $262.65 | 2021-2025 | |
| Pfizer INC. | $208.28 | 2023-2025 | |
| Genzyme Corporation | $173.05 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $127.61 | 2024 | |
| Ardelyx, INC. | $120.58 | 2023-2024 | Ibsrela |
| Celgene Corporation | $108.48 | 2023-2024 | Zeposia |
| Celltrion USA INC. | $89.83 | 2025 | Vegzelma |
| Merck Sharp & Dohme LLC | $86.11 | 2021-2022 | |
| Madrigal Pharmaceuticals | $80.14 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $74.65 | 2024-2025 | Iqirvo |
| Braintree Laboratories, INC. | $57.57 | 2023-2025 | Suflave |
| Qol Medical, LLC | $49.18 | 2023-2025 | Sucraid |
| Phathom Pharmaceuticals, INC. | $42.14 | 2023-2025 | Voquezna |
| Organon LLC | $36.08 | 2023-2025 | Hadlima, Renflexis |
| Endo Pharmaceuticals INC. | $24.52 | 2022 | |
| Nestle Healthcare Nutrition INC. | $23.35 | 2021 | |
| Fresenius Kabi USA, LLC | $22.72 | 2023 | Idacio |
| Aimmune Therapeutics, INC. | $19.22 | 2024 | |
| Redhill Biopharma INC. | $19.02 | 2021 | |
| W. L. Gore & Associates, INC. | $18.00 | 2022 | |
| Daiichi Sankyo INC. | $16.82 | 2024 | Injectafer |
| Csl Behring | $16.65 | 2020 | |
| Evoke Pharma, INC. | $16.17 | 2022 | |
| Novo Nordisk INC | $15.26 | 2025 | |
| Capsovision, INC. | $14.27 | 2025 | Capsocam Plus |
| Ironwood Pharmaceuticals, INC | $13.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colin Leffert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.